Senior insider sale
MOONLAKE IMMUNOTHERAPEUTICS — senior position signals high conviction
$63.49M
3.75M shares
BVF PARTNERS L P/IL plans to sell 3.75M shares of MOONLAKE IMMUNOTHERAPEUTICS valued at approximately $63.49M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Acquired upon the automatic conversion of private shares in connection with the consummation of the Issuer's business combination on April 5, 2022. The private shares were acquired and fully paid for on May 4, 2021.
Merger consideration relating to the Issuer's business combination which occurred on April 5, 2022
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
4/5/2022 | Acquired upon the automatic conversion of private shares in connection with the consummation of the Issuer's business combination on April 5, 2022. The private shares were acquired and fully paid for on May 4, 2021. Merger consideration relating to the Issuer's business combination which occurred on April 5, 2022 | 18.50M | — |
| Total | 18.50M | ||
Units to sell
3.75M
Market value
$63.49M
Units
3.75M
Value
$63.49M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
3/31/2026 | 3.75M | $63.49M | NASDAQ | Planned |
| Total | 3.75M | $63.49M | ||